文献速递糖尿病肥胖与代谢综合征

强化多因素干预对2型糖尿病心血管结局和死亡率的影响(J-DOIT3):一项开放标签、随机对照试验

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-10-24

该多中心开放标签随机对照试验在日本81个中心纳入2542例45-69岁伴高血压或血脂异常且HbA1c≥6.9%的2型糖尿病患者,随机接受强化或常规多因素干预,中位随访8.5年。强化组主要复合终点风险未显著降低(HR 0.81,95%CI 0.63-1.04,P=0.094),但脑血管事件显著减少(HR 0.42,95%CI 0.24-0.74,P=0.002)。

要点

  • 强化组主要复合终点发生109例,常规组133例,HR 0.81(95%CI 0.63-1.04),未达统计学显著。
  • 强化组脑血管事件显著少于常规组(HR 0.42,95%CI 0.24-0.74)。
  • 强化组非严重低血糖发生率41% vs 常规组22%,水肿15% vs 10%。

核心结论

  • 研究结果不完全支持进一步强化多因素干预较当前标准治疗更能预防冠脉事件、脑血管事件和全因死亡的复合终点。
  • 研究结果提示强化干预对2型糖尿病患者预防脑血管事件可能有获益。

研究设计与样本

  • 多中心、开放标签、随机、平行组试验,在日本81个临床中心开展。
  • 2006年6月16日至2009年3月31日随机分配2542例45-69岁伴高血压或血脂异常且HbA1c≥6.9%的2型糖尿病患者,强化组与常规组各1271例,中位随访8.5年(IQR 7.3-9.0)。
  • 随机化采用计算机生成的动态平衡法,按性别、年龄、HbA1c和心血管病史分层;主要分析在意向性治疗人群中进行。
  • 强化组有2例随机后发现不符合条件,被排除于分析。

主要发现

  • 干预期间强化组平均HbA1c 6.8%(51.0 mmol/mol)vs 常规组7.2%(55.2 mmol/mol),收缩压123 mmHg vs 129 mmHg,舒张压71 mmHg vs 74 mmHg,LDL胆固醇85 mg/dL vs 104 mg/dL,均P<0.0001。
  • 主要复合终点强化组109例 vs 常规组133例(HR 0.81,95%CI 0.63-1.04;P=0.094)。
  • 事后分析中全因死亡(HR 1.01,95%CI 0.68-1.51;P=0.95)和冠脉事件(HR 0.86,95%CI 0.58-1.27;P=0.44)两组无差异,脑血管事件强化组显著更少(HR 0.42,95%CI 0.24-0.74;P=0.002)。
  • 非严重低血糖强化组521例(41%)vs 常规组283例(22%),P<0.0001;水肿193例(15%)vs 129例(10%),P=0.0001;其余主要不良事件频率两组无差异。

关键数值与推荐

  • 常规治疗目标:HbA1c<6.9%(52.0 mmol/mol),血压<130/80 mmHg,LDL胆固醇<120 mg/dL(有冠心病史者<100 mg/dL)。
  • 强化治疗目标:HbA1c<6.2%(44.3 mmol/mol),血压<120/75 mmHg,LDL胆固醇<80 mg/dL(有冠心病史者<70 mg/dL)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited evidence suggests that multifactorial interventions for control of glucose, blood pressure, and lipids reduce macrovascular complications and mortality in patients with type 2 diabetes. However, safe and effective treatment targets for these risk factors have not been determined for such interventions. METHODS: In this multicentre, open-label, randomised, parallel-group trial, undertaken at 81 clinical sites in Japan, we randomly assigned (1:1) patients with type 2 diabetes aged 45-69 years with hypertension, dyslipidaemia, or both, and an HbA1c of 6·9% (52·0 mmol/mol) or higher, to receive conventional therapy for glucose, blood pressure, and lipid control (targets: HbA1c <6·9% [52·0 mmol/mol], blood pressure <130/80 mm Hg, LDL cholesterol <120 mg/dL [or 100 mg/dL in patients with a history of coronary artery disease]) or intensive therapy (HbA1c <6·2% [44·3 mmol/mol], blood pressure <120/75 mm Hg, LDL cholesterol <80 mg/dL [or 70 mg/dL in patients with a history of coronary artery disease]). Randomisation was done using a computer-generated, dynamic balancing method, stratified by sex, age, HbA1c, and history of cardiovascular disease. Neither patients nor investigators were masked to group assignment. The primary outcome was occurrence of any of a composite of myocardial infarction, stroke, revascularisation (coronary artery bypass surgery, percutaneous transluminal coronary angioplasty, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, and carotid artery stenting), and all-cause mortality. The primary analysis was done in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00300976. FINDINGS: Between June 16, 2006, and March 31, 2009, 2542 eligible patients were randomly assigned to intensive therapy or conventional therapy (1271 in each group) and followed up for a median of 8·5 years (IQR 7·3-9·0). Two patients in the intensive therapy group were found to be ineligible after randomisation and were excluded from the analyses. During the intervention period, mean HbA1c, systolic blood pressure, diastolic blood pressure, and LDL cholesterol concentrations were significantly lower in the intensive therapy group than in the conventional therapy group (6·8% [51·0 mmol/mol] vs 7·2% [55·2 mmol/mol]; 123 mm Hg vs 129 mm Hg; 71 mm Hg vs 74 mm Hg; and 85 mg/dL vs 104 mg/dL, respectively; all p<0·0001). The primary outcome occurred in 109 patients in the intensive therapy group and in 133 patients in the conventional therapy group (hazard ratio [HR] 0·81, 95% CI 0·63-1·04; p=0·094). In a post-hoc breakdown of the composite outcome, frequencies of all-cause mortality (HR 1·01, 95% CI 0·68-1·51; p=0·95) and coronary events (myocardial infarction, coronary artery bypass surgery, and percutaneous transluminal coronary angioplasty; HR 0·86, 0·58-1·27; p=0·44) did not differ between groups, but cerebrovascular events (stroke, carotid endarterectomy, percutaneous transluminal cerebral angioplasty, and carotid artery stenting) were significantly less frequent in the intensive therapy group (HR 0·42, 0·24-0·74; p=0·002). Apart from non-severe hypoglycaemia (521 [41%] patients in the intensive therapy group vs 283 [22%] in the conventional therapy group, p<0·0001) and oedema (193 [15%] vs 129 [10%], p=0·0001), the frequencies of major adverse events did not differ between groups. INTERPRETATION: Our results do not fully support the efficacy of further intensified multifactorial intervention compared with current standard care for the prevention of a composite of coronary events, cerebrovascular events, and all-cause mortality. Nevertheless, our findings suggest a potential benefit of an intensified intervention for the prevention of cerebrovascular events in patients with type 2 diabetes. FUNDING: Ministry of Health, Labour and Welfare of Japan, Asahi Kasei Pharma, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Kissei Pharmaceutical, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Novo Nordisk, Ono Pharmaceutical, Pfizer, Sanwa Kagaku Kenkyusho, Shionogi, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical, and Takeda.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017. PMID: 29079252. doi:10.1016/S2213-8587(17)30327-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。